Capitol Correspondence - 10.11.21

FDA Advisory Committee Will Hold October Meetings on Moderna and Johnson & Johnson Boosters, Vaccines for Children 5-11

Share this page
The US Capitol building at night.
Share this page
Image of a woman with dark brown hair smiling at the camera. She is wearing a black blouse and a black suit jacket.
Elise Aguilar

Last week, Pfizer submitted a request to the Food & Drug Administration (FDA) for emergency authorization of the COVID-19 vaccine for children ages 5 to 11. Ahead of this request, the FDA’s independent vaccine advisory committee, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), announced it will hold a meeting on October 26 about emergency use authorization for vaccines for 5- to 11-year-olds.  

The VRBPAC announced two additional meetings in October to discuss the use of booster doses of the Moderna and Johnson & Johnson COVID-19 vaccines. The Committee will also hear presentations and discuss the available data on the use of a booster of a vaccine other than the one used for an individual’s initial COVID-19 vaccine series, also known as a “mix and match” booster.  

The schedule for the advisory committee meetings is below: 

  • On Oct. 14, the VRBPAC will discuss the emergency authorization of the Moderna COVID-19 vaccine booster for individuals 18 years of age and older.  

  • On Oct. 15, the VRBPAC will discuss the emergency authorization of Johnson and Johnson’s Janssen COVID-19 vaccine booster for individuals 18 years of age and older. Additionally, the committee will hear a presentation from the National Institute of Health’s National Institute of Allergy and Infectious Diseases on mix and match booster doses. 

  • On Oct. 26, the VRBPAC will discuss the emergency authorization of vaccines for children aged 5 to 11. 

More News

Capitol Correspondence - 08.29.23
HHS Puts Renewal Process in Focus with New Toolkits for States and Partners
Capitol Correspondence - 08.08.23
CMS Releases New State Medicaid Director Letter on Extending Appendix K Flexibilities
Capitol Correspondence - 07.25.23
Medicaid Redeterminations: CMS Seeks to Ensure Coverage Amid Disenrollments